EPS

Treace Medical reports a Q4 revenue dip despite surgeon growth, revealing a strategic shift to lower-priced kits and a challenging 2026 outlook.

The children's apparel giant posts strong Q4 sales, but steep tariff impacts and strategic spending lead to a forecast of declining earnings per share.

With a strong balance sheet and solid growth outlook, AZZ Inc. is launching an intensive conference tour to engage investors and reinforce its market leadership.

Sysco's latest dividend declaration offers more than shareholder returns; it provides a key signal on the health of the global food service industry.

The 3M spin-off navigates a transformative year, posting strong organic growth driven by MedSurg and Dental, despite a reported sales dip from divestitures.

Intelligent power management firm Eaton raises its dividend 6%, backed by record 2025 earnings and a strategic focus on electrification and digitalization.

Stratasys' EcoVadis Gold Medal places it in the top 5% globally, signaling a major shift toward sustainable practices in the additive manufacturing industry.

Perrigo takes a massive $1.3B impairment charge and plans a 7% workforce reduction as it pivots to a 'CORE' business amid a challenging outlook.

The hydration giant posts a 29% revenue jump to $6.7B in its first year, signaling a strong start, but focuses on fixing customer service snags.

The therapy giant reports robust revenue growth and record patient visits, backed by major acquisitions and new 10-year hospital system alliances.

Engineering giant Stantec reports a landmark year with $6.5B revenue, hitting strategic targets early, and raises its dividend, signaling strong future growth.

With a record $411M backlog and surging revenue, Redwire's strategic pivot to defense and space comes at a high cost. Can it turn growth into profit?

Crescent's record production and strategic acquisitions paint a complex picture for investors amid a significant earnings beat but a notable revenue miss.

The diagnostics firm beat Q4 estimates with a 705% profit jump, driven by its Decipher and Afirma tests, and plans to launch two new products in 2026.

The specialty finance giant posted a stunning turnaround, leveraging tech and a hot U.S. market. Here's how it plans to deliver even more in 2026.

The business solutions provider saw record growth in 2025, fueled by client wins, and now plans strategic tech investments while boosting shareholder value.

XPEL reports a massive 50% jump in Q4 net income, yet shares tumble as a revenue miss and a cautious 2026 outlook overshadow the impressive profit growth.

As Wix prepares for a key investor chat, all eyes are on its AI strategy, recent market turbulence, and its path to sustained profitable growth.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

The bank's Q1 earnings surge to $1.25B, driven by its Canadian Western Bank takeover and strategic deals, signaling aggressive pan-Canadian expansion.